GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Primo Nutraceuticals Inc (OTCPK:BUGVF) » Definitions » ROE %

BUGVF (Primo Nutraceuticals) ROE % : -194.75% (As of Apr. 2020)


View and export this data going back to 2019. Start your Free Trial

What is Primo Nutraceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Primo Nutraceuticals's annualized net income for the quarter that ended in Apr. 2020 was $-1.11 Mil. Primo Nutraceuticals's average Total Stockholders Equity over the quarter that ended in Apr. 2020 was $0.57 Mil. Therefore, Primo Nutraceuticals's annualized ROE % for the quarter that ended in Apr. 2020 was -194.75%.

The historical rank and industry rank for Primo Nutraceuticals's ROE % or its related term are showing as below:

BUGVF's ROE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 3.98
* Ranked among companies with meaningful ROE % only.

Primo Nutraceuticals ROE % Historical Data

The historical data trend for Primo Nutraceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Primo Nutraceuticals ROE % Chart

Primo Nutraceuticals Annual Data
Trend Jul16 Jul17 Jul18 Jul19
ROE %
- - -1,341.57 -

Primo Nutraceuticals Quarterly Data
Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -223.66 - -952.62 -35.06 -194.75

Competitive Comparison of Primo Nutraceuticals's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Primo Nutraceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Primo Nutraceuticals's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Primo Nutraceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Primo Nutraceuticals's ROE % falls into.



Primo Nutraceuticals ROE % Calculation

Primo Nutraceuticals's annualized ROE % for the fiscal year that ended in Jul. 2019 is calculated as

ROE %=Net Income (A: Jul. 2019 )/( (Total Stockholders Equity (A: Jul. 2018 )+Total Stockholders Equity (A: Jul. 2019 ))/ count )
=-3.911/( (0.132+-0.415)/ 2 )
=-3.911/-0.1415
=N/A %

Primo Nutraceuticals's annualized ROE % for the quarter that ended in Apr. 2020 is calculated as

ROE %=Net Income (Q: Apr. 2020 )/( (Total Stockholders Equity (Q: Jan. 2020 )+Total Stockholders Equity (Q: Apr. 2020 ))/ count )
=-1.112/( (0.743+0.399)/ 2 )
=-1.112/0.571
=-194.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Apr. 2020) net income data. ROE % is displayed in the 30-year financial page.


Primo Nutraceuticals  (OTCPK:BUGVF) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Apr. 2020 )
=Net Income/Total Stockholders Equity
=-1.112/0.571
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1.112 / 0)*(0 / 2.4285)*(2.4285 / 0.571)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*4.2531
=ROA %*Equity Multiplier
=N/A %*4.2531
=-194.75 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Apr. 2020 )
=Net Income/Total Stockholders Equity
=-1.112/0.571
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-1.112 / -1.112) * (-1.112 / -0.748) * (-0.748 / 0) * (0 / 2.4285) * (2.4285 / 0.571)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.4866 * N/A % * 0 * 4.2531
=-194.75 %

Note: The net income data used here is four times the quarterly (Apr. 2020) net income data. The Revenue data used here is four times the quarterly (Apr. 2020) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Primo Nutraceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Primo Nutraceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Primo Nutraceuticals Business Description

Traded in Other Exchanges
N/A
Address
890 West Pender Street, Suite 440, Vancouver, BC, CAN, V6C 1J9
Primo Nutraceuticals Inc is engaged in the production, processing, retail and branding of cannabis and cannabis-related products. The company offer fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors.